CRACK-TARGET 1: ÉTUDE DESCRIPTIVE DE LA SENSIBILISATION COMPORTEMENTALE OBSERVÉE et ATTENTES
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 15, 2023
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The CRACK-TARGET 1 trial is a research study aimed at understanding a specific behavior called behavioral sensitization in people with crack-cocaine addiction. This means the study will look at how the addiction affects their movements and behaviors over a three-week period. Twenty adults who are currently struggling with crack-cocaine use will be invited to participate. They will wear a device called an actimeter that tracks their physical activity continuously for three weeks and will also have three blood tests to look for certain biological markers related to their addiction.
To be eligible for this study, participants must be over 18 years old, have a serious crack-cocaine use disorder, and preferably use methods like smoking or injecting the drug. The study is specifically looking for an equal number of men and women. Participants should be able to commit to the study for three weeks and be in good health, meaning they should not have any serious psychiatric issues and must weigh more than 40 kg. The trial is not yet recruiting participants, but it aims to provide valuable insights into the behaviors of people dealing with crack-cocaine addiction.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \> 18 years
- • Have a current crack-cocaine use disorder defined as Severe Intensity Use Disorder (6 or more DSM5 criteria), AND preferential use of rapid administration route (intravenous or smoked)
- • Self-identified male or female (n=10 males, n=10 females)
- • Negative pregnancy test for females and use of effective contraception
- • Be affiliated with a social security plan (or PUMA or CSS or AME)
- • Sign an informed consent and commit to a 3-week follow-up in the study
- • Have a weight greater than 40 kg
- Exclusion Criteria:
- • • Patient with a psychiatric disorder or symptoms that are not currently stabilized
- • Patient who is a minor or under protective supervision (curatorship or guardianship)
- • Patient in care at the request of a judicial authority (therapeutic injunction, classification with orientation)
- • Pregnant or breastfeeding women
- • Patients who do not speak French or English sufficiently
- • Patients weighing less than 40 kg
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Florence VORSPAN
Principal Investigator
Hôpital Fernand Widal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported